| Name | Title | Contact Details |
|---|
CellCarta provides integrated analytical platforms in immunology, histopathology, proteomics and genomics, as well as digital pathology & AI.
VBL Therapeutics (NASDAQ: VBLT) is Phase 3 clinical biotechnology company using the machinery of the body to precisely address disease progression. The company has utilized its proprietary gene targeting and antibody platforms to create a pipeline of exquisite solutions for people with difficult to treat cancers and chronic inflammatory diseases. Our lead oncology candidate is Ofravec (VB-111), a first-in-class, targeted anti-cancer gene-therapy agent with a dual mechanism in development to target solid tumors. Ofravec is currently being studied in the OVAL international Phase 3 registration-enabling clinical trial to treat people with platinum-resistant ovarian cancer. Founded in 2000, VBL is based in Modiin, Israel and has recently opened operations in New York.
CELLINK is the first bioink company revolutionizing bioprinting. Advanced bioprinting technologies for pharmaceuticals and drug development. CELLINK is pioneering cell cultivation systems through bioprinting, analysis and liquid handling or bioprocessing.
Boston Biochem is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Orion Genomics is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.